Preand postoperative drug therapy in patients with ovarian endometrioid cysts: a retrospective cohort study


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Endometriosis is a common gynecological disease that affects 10 to 15% of reproductive-aged women. The main symptoms are pain and infertility. One of the treatment strategies is surgery in combination with drug therapy to reduce the risk of recurrent endometriosis. Objective. To retrospectively study the role of drug therapy in the prevention of recurrences after surgical treatment in patients with ovarian endometrioid cysts. Materials and methods. During the study, 600 taken by random sampling histories were retrospectively analyzed in women who had been operated on for ovarian endometrioid cysts. After application of the exclusion criteria, 319 patients were analyzed and divided into two groups: 1) 282 (88%) women with a history of primary endometrioid cysts, 2) 37 (12%) patients with recurrent ovarian endometrioid cysts. Results. Groups 1 and 2 patients were found to have differences in the preoperative use of drugs, such as dydrogesterone, combined oral contraceptives, and gonadotropin-releasing hormone agonists. Conclusion. The absence of hormone therapy or the use of combined oral contraceptives, unlike that of progestogens, in women after surgery for primary ovarian endometriosis is highly likely to lead to recurrent endometriomas. Among the gestagens, dydrogesterone has a number of advantages due to its eff icacy, favorable safety profile, and the possibility of individually selecting a therapy regimen for each patient in the treatment of endometriosis.

Full Text

Restricted Access

About the authors

S. O Dubrovina

Rostov State Medical University, Ministry of Health of Russia

Email: s.dubrovina@gmail.com
Dr. Med. Sci., Professor, the Main Scientific Researcher of Scientific Research Institute of Obstetric and Pediatric 344022, Russia, Rostov-On-Don, per. Nakhichevansky, 29

Yu. D Berlim

Rostov State Medical University, Ministry of Health of Russia

Email: juliaberlim@yandex.ru
PhD, MD, Head of the Consulting and Outpatient Department 344022, Russia, Rostov-On-Don, per. Nakhichevansky, 29

M. A Vovkochina

Rostov State Medical University, Ministry of Health of Russia

Email: jordan-85@inbox.ru
obstetrician gynecologist of Scientific Research Institute of Obstetric and Pediatric 344022, Russia, Rostov-On-Don, per. Nakhichevansky, 29

A. D Aleksandrina

Rostov State Medical University, Ministry of Health of Russia

Email: anna221215@inbox.ru
obstetrician gynecologist 344022, Russia, Rostov-On-Don, per. Nakhichevansky, 29

K. R Bogomolova

Rostov State Medical University, Ministry of Health of Russia

Email: bowsaw@mail.ru
student of the Faculty of Preventive Medicine 344022, Russia, Rostov-On-Don, per. Nakhichevansky, 29

References

  1. Адамян Л.В., ред. Сочетанные доброкачественные опухоли и гиперпластические процессы матки (миома, аденомиоз, гиперплазия эндометрия). Клинические рекомендации по ведению больных. М.; 2015. 94 с
  2. Sound S, Tempest N., Hapangama D.K. Theories on the pathogenesis of endometriosis. Int. J. Reprod. Med. 2014; 2014: 179515. https:// dx.doi.org/10.1155/2014/179515.
  3. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. МКБ-10: N80 ГО:КР259/1. Российское общество акушеров-гинекологов; 2020.
  4. Gargett C.E., Schwab K.E., Deane J.A. Endometrial stem/progenitor cells: the first 10 years. Hum. Reprod. Update. 2016; 22(2): 137-63. https://dx.doi. org/10.1093/humupd/dmv051.
  5. Дубровина С.О., Берлим Ю.Д., Чирский В. С., Мажутин В.Ю., Арешян К.А. Оценка экспрессии маркеров стволовых клеток в эутопическом и эктопическом эндометрии у женщин с эндометриоидными кистами яичников. Акушерство и гинекология. 2019; 3: 78-83.
  6. Kashi A.M., Chaichian S, Ariana S., Fazaeli M., Moradi Y., Rashidi M., Najmi Z. The impact of laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral endometriomas. Int. J. Gynaecol. Obstet. 2017; 136(2): 200-4. https://dx.doi.org/10.1002/ijgo.12046.
  7. Saridogan E. Adolescent endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 209: 46-9. https://dx.doi.org/10.1016/j.ejogrb.2016.05.019.
  8. de Sanctis V., Matalliotakis M., Soliman A.T., Elsefdy H., Di Maio S., Fiscina B. A focus on the distinctions and current evidence of endometriosis in adolescents. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 51: 138-50. https://dx.doi. org/10.1016/j.bpobgyn.2018.01.023.
  9. Guo S.W. Recurrence of endometriosis and its control. Hum. Reprod. Update. 2009; 15(4): 441-61. https://dx.doi.org/10.1093/humupd/dmp007.
  10. Vercellini P, Buggio L., Frattaruolo M.P., Borghi A., Dridi D., Somigliana E. Medical treatment of endometriosis-related pain. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 51: 68-91. https://dx.doi.org/10.1016/j.bpobgyn.2018.01.015.
  11. Santulli P., Tran C., Gayet V, Bourdon M., Maignien C. et al. Oligoanovulation is not a rarer feature in women with documented endometriosis. Fertil. Steril. 2018; 110(5): 941-8. https://dx.doi.org/10.1016/j. fertnstert.2018.06.012
  12. Santulli P, Marcellin L., Menard S., Thubert T., Khoshnood B., Gayet V. et al. Increased rate of spontaneous miscarriages in endometriosis-affected women. Hum. Reprod. 2016; 31(5): 1014-23. https://dx.doi.org/10.1093/humrep/ dew035.
  13. Bernuit D., Ebert A.D., Halis G., Strothmann A., Gerlinger C., Geppert K., Faustmann T. Female perspectives on endometriosis: findings from the uterine bleeding and pain women’s research study. J. Endometriosis. 2011; 3(2): 73-85. https://dx.doi.org/10.5301/JE.2011.8525.
  14. Yong P.J., Alsowayan N., Noga H., Williams C., Allaire C., Lisonkova S., Bedaiwy M.A. CHC for pelvic pain in women with endometriosis: ineffectiveness or discontinuation due to side-effects. Hum. Reprod. Open. 2020; 2020(2): hoz040. https://dx.doi.org/10.1093/hropen/hoz040.
  15. Casper R.F. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil. Steril. 2017; 107(3): 533-6. https://dx.doi.org/10.1016/ j.fertnstert.2017.01.003.
  16. Дубровина С.О., Берлим Ю.Д. Гестагены в терапии эндометриоза. Акушерство и гинекология. 2018; 5: 150-5.
  17. Приказ Министерства здравоохранения Российской Федерации от 20.10.2020 г. № 1130н «Об утверждении Порядка оказания медицинской помощи по профилю "акушерство и гинекология"». Зарегистрировано в Минюсте России 12.11.2020 г. № 60869
  18. Vercellini P., Pietropaolo G., De Giorgi O., Pasin R., Chiodini A., Crosignani P.G. Treatment of symptomatic rectovaginal endometriosis with an estrogen- progestogen combination versus low-dose norethindrone acetate. Fertil. Steril. 2005; 84(5): 1375-87. https://dx.doi.org/10.1016/j.fertnstert.2005.03.083.
  19. Chwalisz K., Surrey E., Stanczyk F.Z. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod. Sci. 2012; 19(6): 563-71. https://dx.doi.org/10.1177/1933719112438061.
  20. Schindler A.E., Campagnoli C., Druckmann R.,Huber J., Pasqualini J.R., Schweppe K.W., Thijssen J.H.H. Reprint of classification and pharmacology of progestins. Maturitas. 2008; 61(1-2): 171-80. https://dx.doi.org/10.1016/j. maturitas.2008.11.013.
  21. Africander D., Verhoog N., Hapgood J.P. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011; 76(7): 636-52. https://dx.doi.org/10.1016/j. steroids.2011.03.001.
  22. Kim S.E., Lim H.H., Lee D.Y., Choi D. The long-term effect of dienogest on bone mineral density after surgical treatment of endometrioma. Reprod. Sci. 2021; 28 (5): 1556 - 62. https://dx.doi.org/10.1007/ s43032-020-00453-7.
  23. Vercellini P., Buggio L., Berlanda N., Barbara G., Somigliana E., Bosari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil. Steril. 2016; 106(7): 1552-71.e2. https://dx.doi.org/10.1016/]. fertnstert.2016.10.022.
  24. Сухих Г.Т., Адамян Л.В., Козаченко А.В., Дубровина С.О., Баранов И.И., Радзинский В.Е., Артымук Н.В., Столярова У.В., Макаренко Т.А., Оразов М.Р., Беженарь В.Ф., Чернуха Г.Е., Чупрынин В.Д., Енькова Е.В., Коротких И.Н., Глухов Е.Ю., Мазитова М.И., Карахалис Л.Ю., Цхай В.Б., Качалина О.В. и др. Дидрогестерон для лечения подтвержденного эндометриоза: ключевые результаты наблюдательного открытого многоцентрового исследования в условиях реальной клиническойпрактики (исследование ОРХИДЕЯ). Акушерство и гинекология: новости, мнения, обучение. 2020; 8(4): 79-81.
  25. Сухих Г.Т., Адамян Л.В., Серов В.Н., Андреева Е.Н., Баранов И.И., Дубровина С.О., Козаченко А.В., Кулешов В.М., Подзолкова Н.М., Прилепская В.Н., Радзинский В.Е., Сонова М.М., Тихомиров А.Л., Уварова Е.В., Чернуха Г.Е., Ших Е.В., Ярмолинская М.И. Резолюция совещания экспертов на тему «Возможности персонализации гормональной терапии эндометриоза с использованием препарата дидрогестерон. Утверждение протокола многоцентрового открытого наблюдательного исследования по применению дидрогестерона для лечения эндометриоза в России (исследование «ОРХИДЕЯ»)». Проблемы репродукции. 2018; 24(5): 41-4
  26. Дубровина С.О., Берлим Ю.Д. Медикаментозное лечение боли, связанной с эндометриозом. Акушерство и гинекология. 2019; 2: 34-40
  27. Jensen J.T., Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil. Steril. 2018; 110(1): 137-52.e1. https://dx.doi.org/10.1016/ j.fertnstert.2018.03.012.
  28. Kitawaki J, Ishihara H, Kiyomizu M., Honjo H. Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain Fertil. Steril. 2008; 89(6): 1831-5. https://dx.doi.org/10.1016/ j.fertnstert.2007.05.052.
  29. Kitawaki J., Kusuki I., Yamanaka K., Suganuma I. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 157(2): 212-6. https://dx.doi.org/10.1016/j.ejogrb.2011.03.012.
  30. Di Francesco A., Pizzigallo D. Use of micronized palmitoylethanolamide and trans-polydatin in chronic pelvic pain associated with endometriosis. An open-label study. Giorn. Ital. Ostetr. Ginecol. 2014; 36(2): 353-8. https:// dx.doi.org/10.11138/giog/2014.36.2.353.
  31. Zupi E., Marconi D., Sbracia M., Zullo F., De Vivo B., Exacustos C., Sorrenti G. Add-back therapy in the treatment of endometriosis-associated pain. Fertil. Steril. 2004; 82(5): 1303-8. https://dx.doi.org/10.1016/j.fertnstert.2004.03.062.
  32. Vercellini P., De Giorgi O., Mosconi P., Stellato G., Vicentini S., Crosignani P.G. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil. Steril. 2002; 77(1): 52-61. https://dx.doi.org/10.1016/ s0015-0282(01)02951-x.
  33. Chen I., Veth V.B., Choudhry A.J., Murji A., Zakhari A., Black A.Y., Agarpao C., Maas J.W. Pre- and postsurgical medical therapy for endometriosis surgery. Cochrane Database Syst. Rev. 2020; (11): CD003678. https://dx.doi. org/10.1002/14651858.CD003678.pub3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies